DDrare: Database of Drug Development for Rare Diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
6	パーキンソン病	1

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02778594 (ClinicalTrials.gov)	September 2005	18/5/2016	Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Benserazide	Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 3-202 and a Single-dose of Controlled-release 100/25 mg Levodopa/Benserazide (Madopar® HBS 125): a Double-blind, Randomised, Four-way Crossover, Placebo-controlled Study in Healthy Volunteers	Parkinson's Disease (PD)	Drug: BIA 3-202;Drug: Placebo;Drug: levodopa 100 mg / benserazide 25 mg	Bial - Portela C S.A.	NULL	Completed	18 Years	45 Years	Both	17	Phase 1	Portugal

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT02778594
(ClinicalTrials.gov)

September 2005

18/5/2016

Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Benserazide

Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 3-202 and a Single-dose of Controlled-release 100/25 mg Levodopa/Benserazide (Madopar® HBS 125): a Double-blind, Randomised, Four-way Crossover, Placebo-controlled Study in Healthy Volunteers

Parkinson's Disease (PD)

Drug: BIA 3-202;Drug: Placebo;Drug: levodopa 100 mg / benserazide 25 mg

Bial - Portela C S.A.

NULL

Completed

18 Years

45 Years

Both

Phase 1

Portugal